Cibus, Inc. (CBUS) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Cibus, Inc. is an agricultural biotechnology company utilizing gene editing (RTDS platform) to develop plant traits for productivity and sustainability. The company operates under an "Up-C" structure, consolidating Cibus Global, LLC. Following a merger completed in May 2023, the company has been focused on commercializing traits in Rice, Canola, and Soybean while managing significant liquidity constraints.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $1.67 million | $0.48 million | $3.05 million | $0.71 million |
| Net Loss (GAAP) | $(201.46) million | $(34.53) million | $(256.91) million | $(60.43) million |
| Net Loss Attributable to Cibus | $(179.97) million | $(26.43) million | $(228.29) million | $(50.51) million |
| Goodwill Impairment | $181.43 million | $0 | $181.43 million | $0 |
| Cash & Equivalents (End of Period) | $28.81 million | $31.88 million | $28.81 million | $31.88 million |
| Operating Cash Flow (9M) | $(44.05) million | $(29.19) million | $(44.05) million | $(29.19) million |
| Current Liabilities | $21.92 million | $21.32 million | $21.92 million | $21.32 million |
| Royalty Liability (Related Parties) | $191.21 million | $165.25 million | $191.21 million | $165.25 million |
Note: All figures in millions unless otherwise noted. Q3 2024 results include a non-cash goodwill impairment charge of $181.4 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 251% in Q3 and 327% in the nine-month period compared to the prior year, driven by collaboration agreements (e.g., Procter & Gamble) and the full inclusion of Cibus Global operations.
- Goodwill Impairment: A significant non-cash impairment charge of $181.4 million was recorded in Q3 2024 due to a decline in the company's stock price and fair value assessment. No such charge existed in the prior year.
- Operating Expenses: Research and Development (R&D) expenses decreased 26% in Q3 2024 compared to Q3 2023, reflecting cost reduction initiatives and lower stock-based compensation. However, on a nine-month basis, R&D increased 35% due to the inclusion of Cibus Global's full operations.
- Financing Activity: The company raised approximately $43.9 million in net proceeds from equity issuances during the first nine months of 2024, including a registered direct offering in June and an underwritten offering in September.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. Cash on hand ($28.8 million) is projected to fund operations only into late Q1 2025 without additional financing.
- Strategic Realignment: In October 2024, the Board approved a workforce reduction of approximately 26 employees and other cost-cutting measures (non-renewal of San Diego facility lease) aimed at saving ~$10 million annually and reducing monthly cash burn by 20%.
- Capital Needs: The company explicitly states it will need to raise additional capital to support its business plan. Failure to do so could result in scaling back or ceasing operations.
- Operational Progress: The company continues to advance traits in Rice (HT1, HT3), Canola (PSR, Sclerotinia resistance), and Soybean. Regulatory environments for gene editing remain favorable in most major markets, with the EU legislative process ongoing.
- Royalty Liability: A significant liability of $191.2 million exists related to royalty payments to related parties, accruing interest expense of $26.0 million for the nine months ended September 30, 2024.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "late Q1 2025" liquidity projection and the substantial doubt disclosure.
- Goodwill Impairment: Confirm the impact of the $181.4 million non-cash charge on the balance sheet and future valuation metrics.
- Royalty Liability Terms: Review the specific triggers for the $191.2 million royalty liability and the conditions under which cash payments to related parties will commence (currently $0.6 million accrued but unpaid).
- Cost Reduction Execution: Monitor the actual realization of the projected $10 million annual savings from the October 2024 restructuring.
- Commercial Milestones: Track the progress of trait transfers to customer germplasm for Rice and Canola, as these are critical for future revenue generation beyond collaboration fees.